Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE N/A. (2021–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $3M | $19M | $42M | — | — |
| Enterprise Value | $3M | $19M | $62M | — | — |
| P/E Ratio → | -0.04 | — | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | 76.6% | 93.0% |
| Operating Margin | — | — | — | -31618.2% | -5131.7% |
| Net Profit Margin | — | — | — | -34745.5% | -5461.3% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | — | — | — | -1711.7% | — |
| ROA | -536.6% | -536.6% | -505.6% | -155.5% | -128.7% |
| ROIC | -203.3% | -203.3% | — | -135.0% | -120.8% |
| ROCE | -326.8% | -326.8% | — | -1532.2% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 7.70 | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | — | — | 7.62 | — |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | -9.90 | -9.90 | -39.93 | -10.56 | -16.62 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | — | — | 0.05 | 0.02 | 0.01 |
| Quick Ratio | — | — | 0.05 | 0.02 | 0.01 |
| Cash Ratio | 0.00 | — | 0.00 | 0.01 | 0.01 |
| Asset Turnover | — | — | — | 0.00 | 0.02 |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 455.06 | 57.41 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $29M | $15M | $21M | $21M |
Clinical Trial Funding Dependency
As reported in financial statements, NKGen's ROIC has consistently trended in negative territory, reaching -24.9% in 2024Q4, which highlights the structural difficulty of generating returns on invested capital while the company remains in a pre-revenue, high-expenditure clinical development phase for its SNK01 platform.
The persistent negative ROIC suggests that the capital deployed into the business is currently being consumed by R&D and manufacturing overhead rather than generating economic value. Investors should monitor whether future clinical milestones can eventually drive a pivot toward positive returns, though current trends indicate a continued decay of invested capital.
Based on recent SEC filings, the company's current ratio has plummeted to a precarious 0.05 as of 2025Q1, indicating that NKGen possesses virtually no short-term liquidity buffer to cover its immediate liabilities or sustain its ongoing research and development expenditures without immediate external capital injections.
This extreme liquidity position suggests that the firm is operating with almost no margin for error, leaving it highly vulnerable to any delays in clinical trial progress or capital market volatility. The lack of a meaningful quick ratio implies that the company is entirely dependent on continuous, dilutive financing to remain a going concern.
According to market data, NKGen trades at a valuation discount relative to peers like Fate Therapeutics, which appears to reflect investor skepticism regarding the autologous business model and the company's ability to scale manufacturing compared to the allogeneic platforms favored by other industry participants.
The gap in valuation multiples suggests that the market is pricing in higher execution risk for NKGen's personalized therapy approach. While this may offer upside if clinical data proves superior, the current peer comparison highlights that the market currently views the company's specific technical path as structurally more challenging than its competitors.
As indicated by the company's financial disclosures, the use of P/E or EV/EBITDA ratios is fundamentally misapplied to NKGen, as these metrics obscure the reality that the firm is a pre-revenue clinical-stage entity where value is driven by binary clinical outcomes rather than current earnings.
Investors should instead focus on metrics like cash runway and R&D efficiency, as traditional valuation multiples provide no insight into the company's actual economic potential. Relying on earnings-based ratios in this context may lead to a false sense of valuation stability, ignoring the high probability of significant dilution required to fund future operations.
Includes 30+ ratios · 4 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NKGN stock.
NKGen Biotech, Inc. Common Stock's current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Based on historical data, NKGen Biotech, Inc. Common Stock is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.